drugset
Drugs / MK-2214
last change Dec 2025 re-read 3 minutes ago

MK-2214

Developed for
Alzheimer disease
Investigated by
Merck Sharp & Dohme LLC

Trials 2

today NCT07033494 · Ph 2 NCT05466422 · Ph 1
2023202420252026202720282029
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 11 trial
Phase 1 NCT05466422 Sep 2022 → Jul 2025 Alzheimer disease Merck Sharp & Dohme LLC Completed No outcome recorded
Phase 21 trial
Phase 2 NCT07033494 Jul 2025 → Apr 2029 expected Alzheimer disease Merck Sharp & Dohme LLC Recruiting No outcome recorded

News releases announcing trial results or a regulatory action · 2

DateIssuerRelease
2025-12-01 Merck Sharp & Dohme LLC Regulatory MSD Showcases Data for Alzheimer’s Disease Candidates MK-2214 and MK-1167 at CTAD 2025 msd.com ↗
In addition, the company announced that MK-2214, a novel candidate targeting the abnormal accumulation and aggregation of tau in the brain, has been granted Fast Track Designation by the U.S. Food and Drug Administration for the treatment of Alzheimer’s disease.
2025-12-01 Merck Sharp & Dohme LLC Regulatory Merck Showcases Data for Alzheimer’s Disease Candidates MK-2214 and MK-1167 at CTAD 2025 merck.com ↗
In addition, the company announced that MK-2214, a novel candidate targeting the abnormal accumulation and aggregation of tau in the brain, has been granted Fast Track Designation by the U.S. Food and Drug Administration for the treatment of Alzheimer’s disease.

All press releases naming this drug 2 releases

DateIssuerRelease

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as MK-2214 ClinicalTrials.gov intervention name — accepted as the source's own label NCT07033494 ↗
1

NCT05466422 ↗
Route Intravenous “MK-2214 in escalating doses as an IV infusion on Days 1, 29, and 57” NCT05466422 ↗